Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

In vivo diagnosis and therapy of Alzheimer's disease

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
BMC Neuroscience20078 (Suppl 1) :P19

  • Published:


  • Peptide
  • Mirror Image
  • Animal Model
  • Transgenic Mouse
  • Neurodegenerative Disorder

Alzheimer's disease (AD) is a progessive neurodegenerative disorder. The 'amyloid cascade hypothesis' assigns the amyloid-beta-peptide (Abeta) a central role in the pathogenesis of Alzheimer's disease. We searched for peptides consisting of the D-enantiomers of amino acids (D-peptides) that bind to Abeta (1–42). D-peptides are thought to be protease resistant and less immunogenic than the respective L-enantiomers and can be identified by mirror image phage display. We carried out a screening of a randomized 12 mer peptide library and identified a dominating D-peptide (D-pep). In vitro experiments verified binding of D-pep to naturally occuring Abeta and showed positive influence of D-pep on Abeta cytotoxicity. In vivo experiments in transgenic mice suggest D-pep to cross the blood-brain-barrier and to reduce Abeta loads in the living brain.

Authors’ Affiliations

IBI-2/INB, Forschungszentrum Jülich, 52425 Jülich, Germany, Juelich, Germany


© Wiesehan et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.